A compound of formula (Ia) or a pharmaceutically acceptable salt thereof, wherein: L 1 is a) C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene, wherein the C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene are each optionally substituted with 1, 2, 3, or 4 fluoro substituents; b) -(CH 2) t -G-(CH 2) p -; wherein t is 0, 1, or 2, p is 0, 1, 2, or 3, and t+p = 0, 1, 2, 3, or 4; or c) -(CH 2) n -G 1 -(CH 2) p -, -(CH 2) n G 2 -(CH 2) p;(CH 2) n C≡C-G 2 -, or -(CH 2) n -C(R 12)=C(R 12)-G 2 -, wherein n is 1, 2, 3, 4, or 5, p is 0, 1, 2, or 3, and n+p = 1, 2, 3, 4, 5, or 6; G is or G 1 is O, C, S, S, S 2, or NR 7; wherein R 7 is H, C 1 -C 4 alkyl, or C 1 -C 4 alkylcarbonyl; G 2 is or wherein G 2 is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, cyano, halogen, C 1 -C 3 alkoxy, and C 1 -C 3 haloalkoxy; R 1 is COOR 9, CONR 9 R 10, CH 2 OR 9, SO 3 R 9, SO 2 NR 9 R 10, PO(OR 9) 2, or tetrazol-5-yl; R 9 is H, C 1 -C 4 alkyl, or aryl; R 10 is H, C 1 -C 4 alkyl, COR 11, OR 9, or SO 2 R 11; R 11 is C 1 -C 4 alkyl; R 12, at each occurrence, is independently H or C 1 -C 4 alkyl; L 4 is -C(R 2) 2 -C(R 3) 2 -, -C(R 2)=C(R 3)-, -C≡C-, or wherein R 2 and R 3 are each H, CH 3, fluoro, or chloro; L 2 is -CH 2 - or a bond; R 4 and R 5 are each independently H, F, CF 3, or C 1 -C 4 alkyl; or R 4 and R 5 together with the carbon to which they are attached form a C 3 -C 5 cycloalkyl, L 3 is C 2 -C 6 alkynylene, wherein the C 2 -C 6 alkynylene is optionally substituted with 1, 2, 3, or 4 fluoro substituents; R 6 is aryl, heteroaryl, heterocyclyl, C 1 -C 10 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 haloalkyl, C 3 -C 8 halocycloalkyl, C 2 -C 10 haloalkenyl, or C 2 -C 10 haloalkynyl; wherein the aryl and heteroaryl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, cyano, halogen, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy; and -C 1 -C 3 alkylene-C 1 -C 3 alkoxy; and wherein the C 1 -C 10 alkyl, C 3 -C 8 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 haloalkyl, C 3 -C 8 halocycloalkyl, C 2 -C 10 haloalkenyl, and C 2 -C 10 haloalkynyl are optionally substituted with a substituent selected from the group consisting of COOR 9', CONR 9' R 10', CH 2 OR 9', SO 3 R 9', SO 2 NR 9' R 10', PO(OR 9') 2, and tetrazol-5-yl; R 9' is H, C 1 -C 4 alkyl, or aryl; R 10' is H, C 1 -C 4 alkyl, COR 11', OR 9', or SO 2 R 11'; R 11' is C 1 -C 4 alkyl; r is 0 or 1; and s is 0 or 1. L 1 is a) C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene, wherein the C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene are each optionally substituted with 1, 2, 3, or 4 fluoro substituents; b) -(CH 2) t -G-(CH 2) p -; wherein t is 0, 1, or 2, p is 0, 1, 2, or 3, and t+p = 0, 1, 2, 3, or 4; or c) -(CH 2) n -G 1 -(CH 2) p -, -(CH 2) n G 2 -(CH 2) p;(CH 2) n C≡C-G 2 -, or -(CH 2) n -C(R 12)=C(R 12)-G 2 -, wherein n is 1, 2, 3, 4, or 5, p is 0, 1, 2, or 3, and n+p = 1, 2, 3, 4, 5, or 6; a) C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene, wherein the C 3 -C 7 alkylene, C 3 -C 7 alkenylene, or C 3 -C 7 alkynylene are each optionally substituted with 1, 2, 3, or 4 fluoro substituents; b) -(CH 2) t -G-(CH 2) p -; wherein t is 0, 1, or 2, p is 0, 1, 2, or 3, and t+p = 0, 1, 2, 3, or 4; or c) -(CH 2) n -G 1 -(CH 2) p -, -(CH 2) n G 2 -(CH 2) p;(CH 2) n C≡C-G 2 -, or -(CH 2) n -C(R 12)=C(R 12)-G 2 -, wherein n is 1, 2, 3, 4, or 5, p is 0, 1, 2, or 3, and n+p = 1, 2, 3, 4, 5, or 6; G is or G 1 is O, C, S, S, S 2, or NR 7; wherein R 7 is H, C 1 -C 4 alkyl, or C 1 -C 4 alkylcarbonyl; G 2 is or wherein G 2 is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, cyano, halogen, C 1 -C 3 alkoxy, and C 1 -C 3 haloalkoxy; R 1 is COOR 9, CONR 9 R 10, CH 2 OR 9, SO 3 R 9, SO 2 NR 9 R 10, PO(OR 9) 2, or tetrazol-5-yl; R 9 is H, C 1 -C 4 alkyl, or aryl; R 10 is H, C 1 -C 4 alkyl, COR 11, OR 9, or SO 2 R 11; R 11 is C 1 -C 4 alkyl; R 12, at each occurrence, is independently H or C 1 -C 4 alkyl; L 4 is -C(R 2) 2 -C(R 3) 2 -, -C(R 2)=C(R 3)-, -C≡C-, or wherein R 2 and R 3 are each H, CH 3, fluoro, or chloro; L 2 is -CH 2 - or a bond; R 4 and R 5 are each independently H, F, CF 3, or C 1 -C 4 alkyl; or R 4 and R 5 together with the carbon to which they are attached form a C 3 -C 5 cycloalkyl, L 3 is C 2 -C 6 alkynylene, wherein the C 2 -C 6 alkynylene is optionally substituted with 1, 2, 3, or 4 fluoro substituents; R 6 is aryl, heteroaryl, heterocyclyl, C 1 -C 10 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 haloalkyl, C 3 -C 8 halocycloalkyl, C 2 -C 10 haloalkenyl, or C 2 -C 10 haloalkynyl; wherein the aryl and heteroaryl are optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, cyano, halogen, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy; and -C 1 -C 3 alkylene-C 1 -C 3 alkoxy; and wherein the C 1 -C 10 alkyl, C 3 -C 8 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 haloalkyl, C 3 -C 8 halocycloalkyl, C 2 -C 10 haloalkenyl, and C 2 -C 10 haloalkynyl are optionally substituted with a substituent selected from the group consisting of COOR 9', CONR 9' R 10', CH 2 OR 9', SO 3 R 9', SO 2 NR 9' R 10', PO(OR 9') 2, and tetrazol-5-yl; R 9' is H, C 1 -C 4 alkyl, or aryl; R 10' is H, C 1 -C 4 alkyl, COR 11', OR 9', or SO 2 R 11'; R 11' is C 1 -C 4 alkyl; r is 0 or 1; and s is 0 or 1.